“Unreal world” or “real world” data in oral anticoagulant treatment of atrial fibrillation

Ben Freedman; Gregory Y. H. Lip

doi:10.1160/TH16-08-0658

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2016; 116(04): 587-589
DOI: 10.1160/TH16-08-0658

Invited Editorial Focus

Schattauer GmbH

“Unreal world” or “real world” data in oral anticoagulant treatment of atrial fibrillation

Ben Freedman

¹Heart Research Institute, Charles Perkins Centre, and Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia

²Department of Cardiology and Anzac Research Institute, Concord Hospital, Concord, New South Wales, Australia

,

Gregory Y. H. Lip

³University of Birmingham Institute of Cardiovascular Science, City Hospital, Birmingham, UK

⁴Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

› Author Affiliations

Abstract

Note: The review process for this manuscript was fully handled by Christian Weber, Editor in Chief.

Full Text

References

References
1 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
2 Potpara TS.. Dabigatran in 'real-world’ clinical practice for stroke prevention in patients with non-valvular atrial fibrillation. Thromb Haemost 2015; 114: 1093-1098.
3 Seeger JD, Bykov K, Bartels DB. et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114: 1277-1289.
4 Villines TC, Schnee J, Fraeman K. et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015; 114: 1290-1298.
5 Hylek EM, Ko D, Cove CL.. Gaps in translation from trials to practice: Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost 2014; 111: 783-788.
6 Lip GY, Clemens A, Noack H. et al. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014; 111: 933-942.
7 Carmo J, Moscoso Costa F, Ferreira J. et al. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost 2016; 116: 754-763.
8 Romanelli RJ, Nolting L, Dolginsky M. et al. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes 2016; 09: 126-134.
9 Bjorck F, Sanden P, Renlund H. et al. Warfarin treatment quality is consistently high in both anti-coagulation clinics and primary care setting in Sweden. Thrombosis Res 2015; 136: 216-220.
10 Chan PH, Huang D, Hai JJ. et al. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. Heart Rhythm 2016; 13: 366-373.
11 Ho CW, Ho MH, Chan PH. et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 2015; 46: 23-30.
12 Levine GN, Jeong YH, Goto S. et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nature Rev Cardiol 2014; 11: 597-606.
13 Hori M, Connolly SJ, Zhu J. et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013; 44: 1891-1896.
14 Wang KL, Lip GY, Lin SJ. et al. Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis. Stroke 2015; 46: 2555-2561.
15 Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
16 Larsen TB, Gorst-Rasmussen A, Rasmussen LH. et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127: 650-656. e5
17 Chan YH, Yen KC, See LC. et al. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation. Stroke 2016; 47: 441-449.
18 Larsen TB, Skjoth F, Nielsen PB. et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Br Med J (Clinical research ed). 2016; 353: i3189.
19 Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND. et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2016 Epub ahead of print.
20 Lip GY, Keshishian A, Kamble S. et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016 Epub ahead of print.